Biomind Labs Inc. (BMNDF)

OTCMKTS · Delayed Price · Currency is USD
0.114
0.00 (0.00%)
At close: Jan 13, 2026
-62.94%
Market Cap 8.84M
Revenue (ttm) n/a
Net Income (ttm) -113.80K
Shares Out 77.57M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,013
Average Volume 2,536
Open 0.114
Previous Close 0.114
Day's Range 0.114 - 0.114
52-Week Range 0.016 - 0.700
Beta -0.72
RSI 44.81
Earnings Date Mar 31, 2026

About Biomind Labs

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Alejandro Antalich
Country Canada
Stock Exchange OTCMKTS
Ticker Symbol BMNDF
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.